Trial Profile
Phase III bioequivalence trial of ondansetron sublingual spray versus ondansetron sublingual tablet (Zofran®).
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 03 Dec 2014
Price :
$35
*
At a glance
- Drugs Ondansetron (Primary) ; Ondansetron
- Indications Nausea and vomiting
- Focus Pharmacokinetics; Registrational
- Sponsors INSYS Therapeutics, Inc
- 03 Dec 2014 New trial record
- 11 Nov 2014 Insys Therapeutics plans to initiate this pivotal trial in 2015, according to a company media release.